HAYA Therapeutics

HAYA Therapeutics

Biotechnologieforschung

Inspired to Transform, The Genome Informs - RNA-Guided Therapeutics to Target Disease Causing Cell-States

Info

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

Branche
Biotechnologieforschung
Größe
11–50 Beschäftigte
Hauptsitz
Lausanne - Switzerland / San Diego - USA
Art
Privatunternehmen
Gegründet
2019
Spezialgebiete
lncRNA, genomic medicines und fibrosis

Orte

  • Primär

    Route De La Corniche 6

    SuperLab Suisse - Batiment Serine

    Lausanne - Switzerland / San Diego - USA, CH

    Wegbeschreibung
  • 3210 Merryfield Row

    JLABS

    San Diego, California 92121, US

    Wegbeschreibung

Beschäftigte von HAYA Therapeutics

Updates

Ähnliche Seiten

Finanzierung